Intracameral antibiotic agents for endophthalmitis prophylaxis: a pharmacokinetic model

Peter E Libre1, Phyllis Della-Latta, Nai Xun Chin

  • 1Columbia University, New York, New York, USA. plibre@optonline.net

Abstract

Insights

Intracameral vancomycin shows promise in preventing Staphylococcus aureus endophthalmitis by inhibiting bacterial growth in the eye. This may enhance the eye's natural defenses post-surgery.

Area of Science:

  • Ophthalmology
  • Infectious Diseases
  • Pharmacology

Background:

  • Endophthalmitis is a severe intraocular infection often caused by Staphylococcus aureus.
  • Prophylaxis against post-operative endophthalmitis is crucial for patient outcomes.

Purpose of the Study:

  • To evaluate the in vitro efficacy of intracameral antibiotics against Staphylococcus aureus.
  • To determine the potential of vancomycin and piperacillin/tazobactam as prophylactic agents for endophthalmitis.

Main Methods:

  • Staphylococcus aureus strains were incubated with vancomycin or piperacillin/tazobactam in vitro.
  • Antibiotic concentrations were serially halved to mimic anterior chamber half-life.
  • Bacterial viability was assessed by measuring colony-forming units (CFU)/mL over 8 hours.

Main Results:

  • Vancomycin significantly inhibited methicillin-resistant S. aureus growth, resulting in 1000-fold higher CFU/mL in controls after 8 hours.
  • Piperacillin/tazobactam demonstrated potent activity, nearly eliminating one strain and reducing another's CFU/mL by 1000-fold.

Conclusions:

  • Intracameral vancomycin exhibits inhibitory effects on Staphylococcus aureus in simulated anterior chamber conditions.
  • These findings suggest intracameral vancomycin could be a viable prophylactic strategy against S. aureus endophthalmitis, potentially aiding the eye's immune response.

Related Concept Videos

Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Pharmacodynamic Models: Linear Concentration–Effect Model01:15

Pharmacodynamic Models: Linear Concentration–Effect Model

The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...